Source: Reuters

EPIRUS Biopharma: BRIEF-Epirus Biopharmaceuticals entered settlement satisfaction amendment with Livzon Mabpharm

* On July 15, co entered into a settlement satisfaction amendment with Livzon Mabpharm Inc - SEC filing

Read full article »
EPIRUS Biopharma's Competitors | EPIRUS Biopharma's News | EPIRUS Biopharma's Financials
Stay up-to-date with the latest news on EPIRUS Biopharma
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on EPIRUS Biopharma